by theprop on 6/27/17, 7:22 AM with 5 comments
by cko on 6/27/17, 3:03 PM
Namzaric: combination of memantine and donepezil, both of which have been generic for a while.
Combinations of hydrocodone and acetaminophen in varying strengths: 5/325, 5/300, 7.5/300, 7.5/325, etc.
Fexmid and Amrix, which are both cyclobenzaprine in different doses and releases.
Moxatag, which is just extended release amoxicillin.
There is one drug that's a capsule form of a drug that was previously a tablet. (Asacol if I recall.) when you open the capsule, the same exact tablet is inside.
Naprelan, or extended release naproxen.
That's just off the top of my head. All a company has to do is extend the release, adjust the dose slightly, add an indication (also treats fibromyalgia!!) or combine two drugs together and bam, it's technically a new drug.
Other less questionable tactics yet of dubious clinical benefit include: isolating a certain enantiomer or creating a "me too" drug - another drug for the same physiologic target - there are so many ACE inhibitors on the market, for example.
As pharmacists, when we see such antics, we roll our eyes and say "are you kidding me."
Most pharmaceutical companies are just marketing companies. Every time I see a doctor prescribe one of these 'new' drugs I suspect there's some kickback involved.
by mtgx on 6/27/17, 7:51 AM
http://khn.org/news/government-protected-monopolies-drive-dr...
by vosper on 6/27/17, 1:18 PM
http://www.econtalk.org/archives/2017/06/robin_feldman_o.htm...